학술논문
509P - FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS
Document Type
Abstract
Author
Source
In Annals of Oncology 1 October 2016 27 Supplement 6:vi168-vi168
Subject
Language
ISSN
0923-7534